Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 41

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 41
---
 its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to
the amount specified on such terms. The obligations of the Agent under the Sales Agreement to sell our common stock are subject to a
number of conditions that we must meet.

We will pay the Agent commissions for the Agent’s services in acting as Agent in the sale
of our common stock at a commission rate equal in the aggregate of 3.0% of the gross proceeds from each sale of our common stock. Because
there is no minimum offering amount required as a condition to this offering, the actual total offering amount, sales commissions and
net proceeds to us, if any, are not determinable at this time. Pursuant to the terms of the Sales Agreement, we have agreed to reimburse
the Agent up to $50,000 for the reasonable fees and expenses of its legal counsel (excluding any periodic due diligence fees) incurred
in connection with entering into the transactions contemplated by the sales agreement. We have also agreed to reimburse the Agent (i)
$5,000 per due diligence update session in connection with each filing of our Annual Report on Form 10-K and (ii) $3,500 per due diligence
update session in connection with each filing of our Quarterly Reports on Form 10-Q, plus any incidental expense incurred by the Agent
in connection therewith. Additionally, we have granted the Agent a right of first refusal for a period of twelve (12) months to
act as sole book-running manager, sole underwriter or sole placement agent for each and every future public or private offering or other
capital-raising financing of equity or equity-linked securities using an underwriter or placement agent by us or any of our successors
or subsidiaries, subject to certain exceptions.

We estimate that the total expenses for the offering, excluding compensation payable to the Agent under the sales agreement, will be
approximately $201,926.

Settlement for sales of our common stock will occur on the first business
day following the date on which any sales are made, or on some other date that is agreed upon by us and the Agent in connection with a
particular transaction, in return for payment of the net proceeds to us. Sales of our common stock under this prospectus supplement will
be settled through the facilities of The Depository Trust Company or by such other means as we and the Agent agree upon. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.

In connection with the sale of